Spotlight On Top Penny Stocks In September 2025

As of late September 2025, the U.S. stock market has experienced a downturn, with major indices such as the Dow Jones Industrial Average, S&P 500, and Nasdaq closing lower due to declines in tech stocks following comments from Federal Reserve Chair Jerome Powell. Amidst these broader market movements, investors often look for opportunities that offer potential growth at lower price points. Penny stocks—though an older term—still represent a compelling investment area by highlighting smaller or newer companies with strong fundamentals. In this article, we explore three penny stocks that stand out due to their solid balance sheets and potential for impressive returns in today's challenging economic landscape.

Name	Share Price	Market Cap	Financial Health Rating
Dingdong (Cayman) (DDL)	$2.03	$443.61M	★★★★★★
Waterdrop (WDH)	$1.92	$708.86M	★★★★★☆
WM Technology (MAPS)	$1.21	$212.07M	★★★★★★
Puma Biotechnology (PBYI)	$4.71	$224.65M	★★★★★★
Sensus Healthcare (SRTS)	$3.16	$51.79M	★★★★★★
Performance Shipping (PSHG)	$1.87	$23.37M	★★★★★★
Golden Growers Cooperative (GGRO.U)	$5.00	$77.45M	★★★★★★
Table Trac (TBTC)	$4.50	$22.41M	★★★★★★
BAB (BABB)	$0.97604	$7.18M	★★★★★★
Lifetime Brands (LCUT)	$3.81	$87.91M	★★★★★☆

Click here to see the full list of 373 stocks from our US Penny Stocks screener.

Here's a peek at a few of the choices from the screener.

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Microvast Holdings, Inc. specializes in battery technologies for electric vehicles and energy storage solutions, with a market cap of approximately $1.25 billion.

Operations: The company generates revenue primarily from its Batteries / Battery Systems segment, totaling $422.61 million.

Market Cap: $1.25B

Microvast Holdings, Inc., with a market cap of approximately US$1.25 billion, focuses on high-performance battery technologies for electric vehicles and energy storage. Despite being unprofitable, the company maintains a sufficient cash runway for over three years and has seen its debt to equity ratio improve significantly over five years. Recent product showcases at BICES 2025 highlighted their fast-charging battery solutions capable of reaching 80% charge in 15-20 minutes, catering to high-intensity applications like mining trucks. Microvast's inclusion in multiple indices reflects its growing recognition within the industry despite ongoing financial challenges.

MVST Revenue & Expenses Breakdown as at Sep 2025

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Cassava Sciences, Inc. is a clinical stage biotechnology company focused on developing drugs for neurodegenerative diseases, with a market cap of approximately $112.07 million.

Operations: Cassava Sciences, Inc. does not currently report any revenue segments as it is in the clinical stage of biotechnology development, concentrating on treatments for neurodegenerative diseases.

Market Cap: $112.07M

Cassava Sciences, Inc., with a market cap of approximately US$112.07 million, is pre-revenue and faces financial challenges, reporting significant net losses in recent quarters. Despite being debt-free and having short-term assets exceeding liabilities, the company has seen its losses increase over the past five years. The stock's volatility remains high compared to most US stocks. Recent developments include positive preclinical results for simufilam in treating TSC-related epilepsy and strategic management changes with Dr. Joseph Hulihan's appointment as Chief Medical Officer to enhance clinical development efforts amidst index reclassifications towards microcap value benchmarks.

SAVA Financial Position Analysis as at Sep 2025

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Clover Health Investments Corp. offers Medicare Advantage plans in the United States and has a market cap of approximately $1.54 billion.

Operations: Clover Health's revenue comes from its Insurance segment, which generated $1.61 billion.

Market Cap: $1.54B

Clover Health Investments, with a market cap of US$1.54 billion, is navigating the penny stock landscape by focusing on operational efficiency and strategic initiatives. Despite being unprofitable, it has reduced losses over five years and maintains a strong cash runway exceeding three years. Recent product enhancements aim to streamline administrative tasks for healthcare providers, while executive board changes highlight its commitment to leadership in predictive analytics. The company's inclusion in multiple Russell indexes reflects its potential growth trajectory despite current financial challenges, including a recent net loss of US$10.58 million for Q2 2025 compared to last year's profit.

CLOV Financial Position Analysis as at Sep 2025

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include MVST SAVA and CLOV.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com